Sarepta Therapeutics (SRPT) Posts Q1 Loss of 75c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Path to Sarepta Therapeutic (SRPT) Eteplirsen Filing Taking Shape - Needham & Company
May 8, 2014 12:35 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q1 results and more details on the path to the eteplirsen filing.
Messer commented, "As we learned last month, Sarepta plans to file the NDA for eteplirsen in Duchenne's muscular dystrophy (DMD) by YE:14 based on recent discussion with the FDA. The company is moving forward on this groundbreaking event and is also preparing to start 3 additional eteplirsen studies as well as a controlled study for 2 additional exon skipping drug for DMD this... More
